Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/ PD ‐1 blockade therapy

Published:2019-06-06 Issue:7 Volume:11 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Zuazo Miren¹,Arasanz Hugo¹,Fernández‐Hinojal Gonzalo²,García‐Granda Maria Jesus¹,Gato María¹,Bocanegra Ana¹,Martínez Maite²,Hernández Berta²,Teijeira Lucía²,Morilla Idoia²,Lecumberri Maria Jose²,Fernández de Lascoiti Angela²,Vera Ruth²^ORCID,Kochan Grazyna¹^ORCID,Escors David¹³^ORCID

Affiliation:

1. Immunomodulation Group Biomedical Research Center of Navarre‐Navarrabiomed Fundación Miguel Servet IdISNA Pamplona Spain

2. Department of Oncology Hospital Complex of Navarre IdISNA Pamplona Spain

3. Division of Infection and Immunity University College London London UK

Funder

Fundación Científica Asociación Española Contra el Cáncer

Instituto de Salud Carlos III

Fundación Española para la Ciencia y la Tecnología

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201910293

Reference42 articles.

1. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

2. Cloning and Sequencing of the VH and YK Genes of an Anti-CD3 Monoclonal Antibody, and Construction of a Mouse/Human Chimeric Antibody

3. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

4. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fractalkine in Health and Disease;International Journal of Molecular Sciences;2024-07-23

2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets;EMBO Molecular Medicine;2024-07-19

3. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

4. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer;Cancer Cell;2024-05

5. Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes in Resectable Gastric Cancer: Analysis from a Western Academic Center;Cancers;2024-04-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3